A record number of small biotechs are now trading below cash. Is this the bottom yet?
For anyone who’s been following biotech news of late, it should be no surprise that many small- to mid-cap players are struggling. But the scope …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
